JP2012507307A5 - - Google Patents

Info

Publication number

JP2012507307A5

JP2012507307A5 JP2011535537A JP2011535537A JP2012507307A5 JP 2012507307 A5 JP2012507307 A5 JP 2012507307A5 JP 2011535537 A JP2011535537 A JP 2011535537A JP 2011535537 A JP2011535537 A JP 2011535537A JP 2012507307 A5 JP2012507307 A5 JP 2012507307A5

Authority

JP

Japan

Prior art keywords

seq

oligonucleotide

administered

oligonucleotide according

polymorphonuclear cells

Prior art date

2009-10-28

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 108091034117 Oligonucleotide Proteins 0.000 claims 25
• 230000005012 migration Effects 0.000 claims 4
• 238000013508 migration Methods 0.000 claims 4
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 3
• 206010061218 Inflammation Diseases 0.000 claims 3
• 230000004054 inflammatory process Effects 0.000 claims 3
• 230000007115 recruitment Effects 0.000 claims 3
• 208000005189 Embolism Diseases 0.000 claims 2
• 230000003828 downregulation Effects 0.000 claims 2
• 210000000056 organ Anatomy 0.000 claims 2
• 239000008194 pharmaceutical composition Substances 0.000 claims 2
• 238000002054 transplantation Methods 0.000 claims 2
• 102100036166 C-X-C chemokine receptor type 1 Human genes 0.000 claims 1
• 102100028989 C-X-C chemokine receptor type 2 Human genes 0.000 claims 1
• 101000947174 Homo sapiens C-X-C chemokine receptor type 1 Proteins 0.000 claims 1
• 101100236208 Homo sapiens LTB4R gene Proteins 0.000 claims 1
• 108010018951 Interleukin-8B Receptors Proteins 0.000 claims 1
• 102100033374 Leukotriene B4 receptor 1 Human genes 0.000 claims 1
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 1
• 230000017531 blood circulation Effects 0.000 claims 1
• 230000003511 endothelial effect Effects 0.000 claims 1
• 239000003527 fibrinolytic agent Substances 0.000 claims 1
• 238000001727 in vivo Methods 0.000 claims 1
• 238000011065 in-situ storage Methods 0.000 claims 1
• 208000027866 inflammatory disease Diseases 0.000 claims 1
• 238000007912 intraperitoneal administration Methods 0.000 claims 1
• 238000001990 intravenous administration Methods 0.000 claims 1
• 208000037906 ischaemic injury Diseases 0.000 claims 1
• 230000004048 modification Effects 0.000 claims 1
• 238000012986 modification Methods 0.000 claims 1
• 208000010125 myocardial infarction Diseases 0.000 claims 1
• 239000002773 nucleotide Substances 0.000 claims 1
• 125000003729 nucleotide group Chemical group 0.000 claims 1
• 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims 1
• 238000004321 preservation Methods 0.000 claims 1
• 238000011084 recovery Methods 0.000 claims 1
• 238000007920 subcutaneous administration Methods 0.000 claims 1
• 238000001356 surgical procedure Methods 0.000 claims 1
• 229960000103 thrombolytic agent Drugs 0.000 claims 1
• 230000000472 traumatic effect Effects 0.000 claims 1